Adhra Al-mawali
Ministry of Health - Sultanate of Oman, Studies and Research, Director of Studies and Research Centre
Dr Adhra Al Mawali, is currently the Director of Studies and Research Centre, Ministry of Health, Oman since 2012. She graduated from Sultan Qaboos University in Medical Sciences and subsequently completed her master and PhD at University of Adelaide in 2008. Her PhD thesis was about Novel Multiparameter Flow Cytometry for the Detection of Leukaemia Associated Phenotypes and Minimal Residual Disease Monitoring in Acute Myeloid Leukaemia (AML) and she found that the oncogenic events of Flt3 internal tandem duplication happen at a stage of stem cells that possess IL-3 alpha-receptor (CD123).
Adhra is the first author of publications in several prestigious international journals like American journal of Clinical pathology, International Journal of laboratory Haematology, Clinical Cytometry, and Journal of Stem Cell Research & Therapy. Her research was chosen as the most outstanding clinical research from the Australian Society for Medical Research 2007 meeting. She was also nominated for World Health Organization Award for Middle Eastern region for control of cancer 2010. She presented her work in many national and international conferences.
Adhra was awarded ‘The Woman Excellence Award’ in the Health Sector in 2011, as well as being selected as one of the 40 super achievers in the Sultanate of Oman in a Book entitled ‘Jewels of Oman’. She was also the winner for the best poster in the International Conference in laboratory Medicine 2010, Muscat, Oman. She is a member of Member of Oman Medical Journal editorial Board. Dr Adhra is a chairperson and a member in several important committees such as the Steering Committee for ‘Health Vision 2050’ for Oman, Chairperson for preparing the strategic study" 2050 vision for health research" and Chairperson for preparing the strategic study "2050 vision for Medical Equipment and healthcare technology". She is a rapporteur and member of Research Funding committee in Ministry of Health and also Chairperson for the committee of funding Health Institutes' students research projects (FURAB) by the Research Council. Dr Adhra has participated in an intensive course (Middle East Health Leadership Programme) in Abu Dhabi given by INSEAD The Business School for the world in 2014 and a recent one in June 2015 at Mc Master University in Canada about Research Knowledge Translation.
Adhra’s project will have an immediate impact on patient management as many more patients will be screened using leukaemic stem cell approach and a significant number of patients at risk of relapse of leukaemia will be identified and offered alternate therapeutic strategies such as haemopoietic stem cell transplantation or novel tailored therapies. The most promising approach points to the potent anti-leukaemic effects of 'stem cell-targeted' drug therapy.
Patients with AML who are likely to relapse and were previously missed, will be detected early as the CD34+CD38-CD123+ phenotype is a more specific diagnostic tool than blast cell associated markers . Hence, it will contribute to generating greater in depth knowledge about AML. Total health care costs will be reduced as patients will be detected early with a refined diagnostic tool, which in turn will reduce use of unnecessary chemotherapy protocols and treatment modalities.
Phone: 0096892839997
Address: Tel:+968 24697551/ 24695921
Fax: +968 24696702
P.O.Box 393, PC 113 Muscat-Oman
Adhra is the first author of publications in several prestigious international journals like American journal of Clinical pathology, International Journal of laboratory Haematology, Clinical Cytometry, and Journal of Stem Cell Research & Therapy. Her research was chosen as the most outstanding clinical research from the Australian Society for Medical Research 2007 meeting. She was also nominated for World Health Organization Award for Middle Eastern region for control of cancer 2010. She presented her work in many national and international conferences.
Adhra was awarded ‘The Woman Excellence Award’ in the Health Sector in 2011, as well as being selected as one of the 40 super achievers in the Sultanate of Oman in a Book entitled ‘Jewels of Oman’. She was also the winner for the best poster in the International Conference in laboratory Medicine 2010, Muscat, Oman. She is a member of Member of Oman Medical Journal editorial Board. Dr Adhra is a chairperson and a member in several important committees such as the Steering Committee for ‘Health Vision 2050’ for Oman, Chairperson for preparing the strategic study" 2050 vision for health research" and Chairperson for preparing the strategic study "2050 vision for Medical Equipment and healthcare technology". She is a rapporteur and member of Research Funding committee in Ministry of Health and also Chairperson for the committee of funding Health Institutes' students research projects (FURAB) by the Research Council. Dr Adhra has participated in an intensive course (Middle East Health Leadership Programme) in Abu Dhabi given by INSEAD The Business School for the world in 2014 and a recent one in June 2015 at Mc Master University in Canada about Research Knowledge Translation.
Adhra’s project will have an immediate impact on patient management as many more patients will be screened using leukaemic stem cell approach and a significant number of patients at risk of relapse of leukaemia will be identified and offered alternate therapeutic strategies such as haemopoietic stem cell transplantation or novel tailored therapies. The most promising approach points to the potent anti-leukaemic effects of 'stem cell-targeted' drug therapy.
Patients with AML who are likely to relapse and were previously missed, will be detected early as the CD34+CD38-CD123+ phenotype is a more specific diagnostic tool than blast cell associated markers . Hence, it will contribute to generating greater in depth knowledge about AML. Total health care costs will be reduced as patients will be detected early with a refined diagnostic tool, which in turn will reduce use of unnecessary chemotherapy protocols and treatment modalities.
Phone: 0096892839997
Address: Tel:+968 24697551/ 24695921
Fax: +968 24696702
P.O.Box 393, PC 113 Muscat-Oman
less
Related Authors
InterestsView All (7)
Uploads
Papers by Adhra Al-mawali